Breast Cancer Coverage from Every Angle
Editor:
William J. Gradishar, MD, FACP, FASCO
Advertisement
Advertisement

Ongoing CE Activities

A Targeted Approach to Optimizing the Treatment of HER2+ Breast Cancer
An Interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast Cancer
Are These Patients With HR-Positive/HER2-Negative EBC at High Risk of Recurrence? Test Yourself With These Patient Cases
Beyond the Guidelines: Clinical Investigator Perspectives on the Management of HER2-Low Breast Cancer
Breast Cancer Prevention, Screening, Diagnosis, and Treatment
Community Collaboration: Application of CDK 4/6 Inhibitors in the Treatment of HR-Positive/HER2-Negative Early Breast Cancer
Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Keeping the Outcome in Mind: Applying Best Practices for Managing HR+/HER2- EBC at High Risk of Recurrence
Multigene and Biomarker Testing in Breast Cancer
Neoadjuvant/Adjuvant Treatment for Breast Cancer With SABCS Updates
Novel and Emerging Evidence in Early-Stage Breast Cancer
Oncology Today with Dr Neil Love: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer
Oncology Today with Dr Neil Love: Understanding the Current and Future Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
Optimizing Use of PARP Inhibitors in Early-Stage and Metastatic Breast Cancer Patients With DNA Damage Repair Pathway Mutations
Recorded Presentations from the NCCN 2023 Breast Cancer Congress With Updates From The 2022 San Antonio Breast Cancer Symposium
Striving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer
Targeted Approaches to Treating Triple-Negative Breast Cancer: Cases From the Community
The Role of Lifestyle and the Environment in Breast Cancer Risk
Virtual Case Library: Metastatic Triple-Negative Breast Cancer
What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Hormonal Therapy for Hormone Receptor-Positive Breast Cancer
Why Do I Need Adjuvant Therapy? Communicating the Risks for HR-Positive, HER2-Negative EBC at High Risk of Recurrence
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer
Copyright © 2024 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.